Fulfilling the Promise of Precision Medicine
Caris Life Sciences® was founded because of an idea – that personalized and precise information can improve healthcare for everyone. As an innovative biotechnology company, we’re actively working to fulfill the promise of precision medicine through our unique and transformative platforms to help patients with cancer and other complex diseases.
ADAPT Biotargeting System™ is an unbiased profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System has potential applications spanning therapeutic development, drug delivery, diagnostics and disease monitoring.
Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today.
Headquartered in the Dallas-Fort Worth Metroplex, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets.